Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01630889 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
A Phase 2 study, sponsored by Kyntra Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01630889 is a Phase 2 study that has completed, run by Kyntra Bio. The registered enrollment target is 15 participants.
The verdict
NCT01630889, a Phase 2 study, has completed, sponsored by Kyntra Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study.
Interventions
- DRUG Roxadustat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-05-18 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01630889
The ClinicalTrials.gov registry entry for NCT01630889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyntra Bio, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Roxadustat is the first listed.
NCT01630889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01630889 about?
NCT01630889 is a clinical study titled "Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease". The purpose of this open-label extension study is to evaluate long-term efficacy and safety of roxadustat in maintaining hemoglobin (Hb) in participants with dialysis and non-dialysis chronic kidney disease (CKD) who have completed the Treatment Period of a roxadustat FibroGen-sponsored anemia study...
What is the current status of trial NCT01630889?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-05-18. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT01630889?
The interventions under investigation include: Roxadustat (DRUG).
Who is sponsoring clinical trial NCT01630889?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.